Immunotherapy for HCC: Evidence, Guidance, and Resources for the Multidisciplinary Care Team

In this downloadable slideset, experts provide multidisciplinary insights into the optimal use of immune checkpoint inhibitors for advanced HCC.
Lipika Goyal, MD
Amit G. Singal, MD, MS
Format: Microsoft PowerPoint (.ppt)
File Size: 5.30 MB
Released: April 30, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Genentech, a member of the Roche Group

Related Content

In this slideset from Clinical Care Options (CCO), experts provide insights on the optimal use of CAR T-cell therapy for lymphomas

person default Caron A. Jacobson, MD Released: June 16, 2021

In this slideset from Clinical Care Options (CCO), experts provide insights on CAR T-cell strategies for myeloma

Noopur Raje, MD Released: June 16, 2021

In this slideset from Clinical Care Options (CCO), experts provide insights on the optimal use of CAR T-cell therapy for ALL

Jae H. Park, MD Released: June 16, 2021

From Clinical Care Options (CCO), video featuring expert insights on the integration of CAR T-cell therapy into community care

person default Caron A. Jacobson, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 14, 2021 Expired: June 13, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue